Biomatics Capital is a venture capital firm that invests in transformational, data-enabled innovation at the intersection of healthcare and technology. The Seattle-based firm focuses on early-stage companies in genomics, digital health, diagnostics, and therapeutics.
44% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $76.9M (across 16 rounds with reported amounts).
Portfolio
10
Fund Size
$300M
Top Stage
Series A
Last 12 Mo
0
Team
BN
Boris Nikolic
Managing Director
JS
Julie Sunderland
Managing Director
SR
Saif Rehman
Research Analyst
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
16 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| VVerve Therapeutics | Series C | $213M | Oct 2024 |
 eGenesis | Series B | $100M | Jan 2024 |
 Encodia | Series C | $75M | Jan 2021 |
 Omniome | Series C | $60M | Jan 2020 |
| TThrive Earlier Detection | Series A | $110M | May 2019 |
| VVerve Therapeutics | Series A | $58.5M | Jan 2019 |
| TThrive Earlier Detection | Series A | $110M | Jan 2019 |
 AiCure | Series C | $56M | Jan 2019 |
| VVerana | Growth | $30M | Jul 2018 |
| Omniome | Series B | $60M | Jul 2018 |
| Omniome | Series B | $60M | Jan 2018 |
| eGenesis | Series A | $38M | Mar 2017 |
 Aledade | Series B | $20M | Jan 2017 |
| VVerve Therapeutics | Series B | $94M | — |
 BlackThorn Therapeutics | Series A | $14M | — |
 Compass Therapeutics | Series A | $132M | — |
Top Co-Investors
ARCH Venture Partners10 shared
GV8 shared
Altitude Life Science Ventures4 shared
Casdin Capital4 shared
Primary Venture Partners3 shared
DCVC3 shared
Domain Associates3 shared
Alexandria Venture Investments3 shared
Nan Fung Life Sciences3 shared
Decheng Capital3 shared
Wellington Management3 shared
F-Prime Capital3 shared
Decent Capital2 shared
Pivotal Life Sciences2 shared
Third Rock Ventures2 shared
Perceptive Advisors2 shared
The Invus Group, LLC2 shared
Khosla Ventures2 shared
Alta Partners2 shared
Hillhouse Investment2 shared
Last updated: 20 October 2026